Aditi Shah

发表

Association Between Weight Gain and the Incidence of Cardiometabolic Conditions Among People Living with HIV-1 at High Risk of Weight Gain Initiated on Antiretroviral Therapy

G. McComsey, B. Bookhart, M. Lafeuille, 2022, Infectious Diseases and Therapy.

Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey

P. Lefebvre, D. Pilon, M. Zhdanava, 2022, Neuropsychiatric disease and treatment.

Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey

P. Lefebvre, D. Pilon, M. Zhdanava, 2022, Neuropsychiatric disease and treatment.

NDT_A_379985 2003..2019

P. Lefebvre, D. Pilon, M. Zhdanava, 2022 .

Association Between Weight Gain and the Incidence of Cardiometabolic Conditions Among People Living with HIV-1 at High Risk of Weight Gain Initiated on Antiretroviral Therapy

G. McComsey, B. Bookhart, M. Lafeuille, 2022, Infectious Diseases and Therapy.

Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA

T. Fitzgerald, P. Lefebvre, D. Pilon, 2022, Dermatology and Therapy.

Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy

L. Citrome, J. Sheehan, P. Lefebvre, 2021, Journal of medical economics.

Neonatal Appendicitis with Cow Milk Protein Allergy

J. Mandke, Aditi Shah, 2020, Indian Pediatrics.

Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study.

E. Muser, I. Khilfeh, P. Lefebvre, 2023, Urologic oncology.

A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia.

P. Lefebvre, C. Benson, D. Pilon, 2023, Drugs - real world outcomes.

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

S. Feldman, T. Fitzgerald, P. Lefebvre, 2023, Dermatology and Therapy.

Incidence of cardiometabolic outcomes among people living with HIV‐1 initiated on integrase strand transfer inhibitor versus non‐integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States

P. Rebeiro, B. Bookhart, M. Lafeuille, 2023, Journal of the International AIDS Society.

Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors

B. Bookhart, M. Lafeuille, C. Rossi, 2022, Journal of comparative effectiveness research.

Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement.

B. Vundinti, C. Shanmukhaiah, Aditi Shah, 2023, Cancer genetics.

Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on Esketamine intranasal spray and covered by US commercial health plans.

K. Joshi, D. Pilon, M. Zhdanava, 2023, Journal of medical economics.

Characteristics of Real-World Commercially Insured Patients With Treatment-Resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.

P. Lefebvre, K. Joshi, D. Pilon, 2022, Clinical therapeutics.

Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States

K. Joshi, D. Pilon, M. Zhdanava, 2023, Journal of medical economics.

Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States

K. Joshi, D. Pilon, M. Zhdanava, 2024, Drugs - real world outcomes.